1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)


Table 1: 
Comparison of relative perfusion parameters among pretreatment, 1 week, and 1 year groups
rCBFrCBVrMTT
Pre1 week1 yearPPre1 week1 yearPPre1 week1 yearP
ACA territory0.86 ± 0.060.95 ± 0.040.97 ± 0.070.001.02 ± 0.031.00 ± 0.010.99 ± 0.040.121.17 ± 0.051.03 ± 0.041.01 ± 0.060.00
MCA territory0.81 ± 0.041.06 ± 0.051.03 ± 0.070.001.13 ± 0.091.12 ± 0.071.07 ± 0.080.061.41 ± 0.061.08 ± 0.041.07 ± 0.040.00
PCA territory0.96 ± 0.061.00 ± 0.040.99 ± 0.020.081.02 ± 0.061.02 ± 0.041.03 ± 0.050.571.07 ± 0.051.05 ± 0.051.03 ± 0.060.06
Basal ganglia0.85 ± 0.060.97 ± 0.040.96 ± 0.040.001.02 ± 0.070.98 ± 0.021.01 ± 0.050.161.20 ± 0.061.06 ± 0.041.05 ± 0.040.00
Anterior CWS0.78 ± 0.030.97 ± 0.030.96 ± 0.020.001.08 ± 0.051.06 ± 0.061.05 ± 0.070.241.41 ± 0.051.10 ± 0.051.09 ± 0.040.00
Posterior CWS0.77 ± 0.031.00 ± 0.020.98 ± 0.030.001.10 ± 0.071.09 ± 0.091.04 ± 0.060.111.43 ± 0.101.07 ± 0.061.08 ± 0.060.00
IWS0.80 ± 0.040.94 ± 0.030.93 ± 0.040.001.05 ± 0.061.02 ± 0.051.04 ± 0.050.191.29 ± 0.101.09 ± 0.051.11 ± 0.070.00
  • 

    Note:—For rCBF and rMTT, except in PCA territory, pretreatment vs 1 week or 1 year after CAS, P < 0.01; 1 week vs 1 year, P > 0.05.